

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PROLLENIUM US INC.,
Petitioner,

v.

ALLERGAN INDUSTRIE, SAS,
Patent Owner.

IPR2019-01505, Patent 8,450,475 B2
IPR2019-01506, Patent 8,357,795 B2
IPR2019-01508, Patent 9,238,013 B2
IPR2019-01509, Patent 9,358,322 B2
IPR2019-01617, Patent 8,822,676 B2
IPR2019-01632, Patent 8,357,795 B2
IPR2020-00084, Patent 9,089,519 B2

**JOINT STIPULATION TO MODIFY DUE DATES 1–3
IN SCHEDULING ORDER¹**

¹ Authorization for the use of a joint caption page was received on April 27, 2020. Neither party opposes the use of a joint caption page. An identical paper has been filed in each case recited in the consolidated caption.

IPR2019-01505, Patent 8,450,475 B2; IPR2019-01506, Patent 8,357,795 B2; IPR2019-01508, Patent 9,238,013 B2; IPR2019-01509, Patent 9,358,322 B2; IPR2019-01617, Patent 8,822,676 B2; IPR2019-01632, Patent 8,357,795 B2; IPR2020-00084, Patent 9,089,519 B2

Prollenium US Inc. (“Petitioner”) and Allergan Industrie, SAS (“Patent Owner”), by and through their respective counsel of record, hereby stipulate as follows:

On April 13, 2020, the Scheduling Order in the Inter Partes Review of U.S. Patent No. 8,450,475 (IPR2019-01505), U.S. Patent No. 8,357,795 (IPR2019-01506), U.S. Patent No. 9,238,013 (IPR2019-01508), U.S. Patent No. 9,358,322 (IPR2019-01509), U.S. Patent No. 8,822,676 (IPR2019-01617), U.S. Patent No. 8,357,795 (IPR2019-01632), and U.S. Patent No. 9,089,519 (IPR2020-00084) set forth “due dates for the parties to take action in this trial,” and further stated that the “parties may stipulate different dates for DUE DATES 1, 2, 5, and 6, as well as the portion of DUE DATE 3 related to Patent Owner’s sur-reply (earlier or later, but no later than DUE DATE 7).” *Id.* at 7.

Patent Owner and Petitioner hereby stipulate to modify DUE DATES 1–3 as follows:

DUE DATE 1: August 26, 2020

DUE DATE 2: November 4, 2020

DUE DATE 3: December 2, 2020

Patent Owner’s Sur-Reply to Petitioner’s Reply

IPR2019-01505, Patent 8,450,475 B2; IPR2019-01506, Patent 8,357,795 B2;
IPR2019-01508, Patent 9,238,013 B2; IPR2019-01509, Patent 9,358,322 B2;
IPR2019-01617, Patent 8,822,676 B2; IPR2019-01632, Patent 8,357,795 B2;
IPR2020-00084, Patent 9,089,519 B2

This stipulation does not affect or otherwise modify the portion of DUE
DATE 3 that relates to Patent Owner's Reply to Petitioner's Opposition to the
Motion to Amend or Patent Owner's Revised Motion to Amend, or DUE DATES
5–8 in the Scheduling Order.

Respectfully Submitted,

Date: July 14, 2020

/Warren Thomas/

Warren J. Thomas

Reg. No. 70,581

Petitioner, Prolenium US Inc.

Date: July 14, 2020

/Anthony M. Insogna/

Anthony M. Insogna

Reg. No. 35,203

Patent Owner, Allergan Industrie, SAS

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served on the counsel for Petitioner a true and correct copy of this Joint Stipulation to Modify Due Dates 1–3 in Scheduling Order by electronic means at the following address of record:

mcc.prolenium.ipr@mcciplaw.com

Dated: July 14, 2020

/Anthony M. Insogna/

Anthony M. Insogna (Reg. No. 35,203)

Jones Day

4655 Executive Drive, Suite 1500

San Diego, CA 92121-3134

Tel.: (858) 314-1200

Fax.: (844) 345-3178

Attorney for Patent Owner